• Featured Product
  • KD/KO Validated

TMEM106B (150-274aa) Polyclonal antibody

TMEM106B (150-274aa) Polyclonal Antibody for WB, IHC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

WB, IHC, IF, ELISA

Conjugate

Unconjugated

Cat no : 20995-1-AP

Synonyms

TMEM106B, Transmembrane protein 106B



Tested Applications

Positive WB detected inA549 cells, HeLa cells, HepG2 cells
Positive IHC detected inrat brain tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:2000
Immunohistochemistry (IHC)IHC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

20995-1-AP targets TMEM106B (150-274aa) in WB, IHC, IF, ELISA applications and shows reactivity with human, mouse samples.

Tested Reactivity human, mouse
Cited Reactivityhuman, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen TMEM106B (150-274aa) fusion protein Ag14264
Full Name transmembrane protein 106B
Calculated Molecular Weight 31 kDa
Observed Molecular Weight 31-35 kDa, 40-55 kDa
GenBank Accession NumberBC033901
Gene Symbol TMEM106B
Gene ID (NCBI) 54664
RRIDAB_10694293
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

TMEM106B is a genetic risk factor for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). Amyotrophic lateral sclerosis (ALS), like FTLD-TDP, is characterized by pathological TDP-43 inclusions. TMEM106B expression in the brain may be linked to mechanisms of disease in FTLD-TDP and risk alleles confer genetic susceptibility by increasing gene expression. TMEM106B can be showed as 31-55 kDa and 70-90 kDa (Glycosylated or Dimer) form in western blot test. (PMID: 27543298, 22895706, PMID: 23136129).

Protocols

Product Specific Protocols
WB protocol for TMEM106B (150-274aa) antibody 20995-1-APDownload protocol
IHC protocol for TMEM106B (150-274aa) antibody 20995-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
human

Cell

Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases.

Authors - Andrew Chang
humanWB

J Neuroinflammation

Progranulin haploinsufficiency mediates cytoplasmic TDP-43 aggregation with lysosomal abnormalities in human microglia

Authors - Wonjae Sung
humanWB

J Neurosci

TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways.

Authors - Chen-Plotkin Alice S AS
humanWB

Alzheimers Res Ther

TMEM106B expression is reduced in Alzheimer's disease brains.

Authors - Jun-Ichi Satoh
mouseIF

Mol Brain

TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III.

Authors - Mi-Hee Jun
humanWB

PLoS One

Construction of ceRNA network to identify the lncRNA and mRNA related to non-small cell lung cancer.

Authors - Kui Xiao

Reviews

The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.


FH

Carolyn (Verified Customer) (02-18-2022)

good signal, low background

  • Applications: Western Blot
  • Primary Antibody Dilution: 1:1000
  • Cell Tissue Type: Human brain tissue extract